Medical University of Bialystok
umb.edu.plLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
67
Active
18
Phase 3
2
Total enrollment
8,490,541
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atorvastatin 40 Mg Oral | — | — | — | — | — | 1 | |
| Desmopressin | — | — | — | — | — | 1 | |
| intravenous infusion NaCl | — | — | — | — | — | 1 | |
| Metformin Hydrochloride | — | — | — | — | — | 1 | |
| SRP+iPRF | — | — | — | — | — | 1 | |
| SRP+ANB+SURG | — | — | — | — | — | 1 | |
| Semaglutide Pill | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2025-12-30
- 2025-12-31
- 2026-08-31
- 2026-12-31
- 2027-09-30
Top conditions
- Obesity13
- PreDiabetes4
- Glaucoma3
- Acute Coronary Syndrome3
- Coronary Artery Disease3
- Periodontitis2
- Healthy2
- Diabetes Mellitus2
Frequently asked questions about Medical University of Bialystok
- How many clinical trials does Medical University of Bialystok have on ClinicalTrials.gov?
- Medical University of Bialystok is listed as the lead sponsor on 67 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Medical University of Bialystok's trials are in Phase 3?
- 2 of Medical University of Bialystok's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Medical University of Bialystok focus on?
- Medical University of Bialystok's most-studied conditions on ClinicalTrials.gov are Obesity, PreDiabetes, Glaucoma, Acute Coronary Syndrome, Coronary Artery Disease.
- When are Medical University of Bialystok's next clinical trial readouts?
- Medical University of Bialystok has 6 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of the Influence of PRF (Platelet-rich Fibrin) on the Clinical Parameters and the Concentration of Selected Inflammation Mediators in GCF (Gingival Crevice Fluid) of Patients With Periodontitis”, expected around 2025-06-30.